ISDA: 8FP3

Deposition Date 2023-01-03

Release Date 2023-04-05

Last Version Date 2024-10-09

Entry Detail

PDB ID:

8FP3

Keywords:

TRANSFERASE/INHIBITOR

Title:

PKCeta kinase domain in complex with compound 11

Biological Source:

Source Organism(s):

Homo sapiens (Taxon ID: 9606)

Expression System(s):

Spodoptera frugiperda

Method Details:

Experimental Method:

X-RAY DIFFRACTION

Resolution:

2.30 Å

R-Value Free:

0.25

R-Value Work:

0.19

Space Group:

P 21 21 21

Download Validation Report

Macromolecular Entities

Structures with similar UniProt ID

Protein Blast

Polymer Type:polypeptide(L)
Molecule:Protein kinase C eta type
Gene (Uniprot):PRKCH
Mutagens:S675E
Chain IDs:A
Chain Length:353
Number of Molecules:1
Biological Source:Homo sapiens

UniProt ID:P24723 Pfam ID:PF00069, PF00433 EC:2.7.11.13

Modified Residue

Compound ID	Chain ID	Parent Comp ID	Details	2D Image
TPO	A	THR	modified residue

Ligand Molecules

Y3I

Primary Citation

Design and Synthesis of Functionally Active 5-Amino-6-Aryl Pyrrolopyrimidine Inhibitors of Hematopoietic Progenitor Kinase 1.

Gallego, R.A, Bernier, L, Chen, H, Cho-Schultz, S, Chung, L, Collins, M, Del Bel, M, Elleraas, J, Costa Jones, C, Cronin, C.N, Edwards, M, Fang, X, Fisher, T, He, M, Hoffman, J, Huo, R, Jalaie, M, Johnson, E, Johnson, T.W, Kania, R.S, Kraus, M, Lafontaine, J, Le, P, Liu, T, Maestre, M, Matthews, J, McTigue, M, Miller, N, Mu, Q, Qin, X, Ren, S, Richardson, P, Rohner, A, Sach, N, Shao, L, Smith, G, Su, R, Sun, B, Timofeevski, S, Tran, P, Wang, S, Wang, W, Zhou, R, Zhu, J, Nair, S.K.Show

J.Med.Chem. 66 4888 4909 (2023)

PMID: 36940470 DOI: 10.1021/acs.jmedchem.2c02038

Abstact

Immune activating agents represent a valuable class of therapeutics for the treatment of cancer. An area of active research is expanding the types of these therapeutics that are available to patients via targeting new biological mechanisms. Hematopoietic progenitor kinase 1 (HPK1) is a negative regulator of immune signaling and a target of high interest for the treatment of cancer. Herein, we present the discovery and optimization of novel amino-6-aryl pyrrolopyrimidine inhibitors of HPK1 starting from hits identified via virtual screening. Key components of this discovery effort were structure-based drug design aided by analyses of normalized B-factors and optimization of lipophilic efficiency.

Legend

Protein

Chemical

Disease

Primary Citation of related structures

Abstact

Feedback Form